ICMT

Across TCGA pan-cancer cohorts, ICMT mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ICMT data layer compared with 20 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher ICMT mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated ICMT expression acts as an unfavorable survival marker, although some lineages such as PDAC and LSCC show a favorable association.

CCRCC, PDAC, and LUAD are the cancer types where ICMT mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Tertile	All	0.664	1.000	.015	14	view →
PDAC	OS	Median	III,IV	0.938	0.311	.010	12	view →
LUAD	OS	Quartile	All	0.502	0.983	.012	6	view →
GBM	DFS	Median	All	0.586	0.767	.041	1	view →
LSCC	OS	Median	II,III,IV	1.000	0.833	.049	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ICMT–CCRCC (OS)

Open the CCRCC breakdown →